Medicenna Therapeutics CorpTSX:MDNAView on OTCQX International
- LAST PRICE1.5700
- TODAY'S CHANGE (%)0.0800 (5.3691%)
- Bid / Lots1.5500/ 33
- Ask / Lots1.5900/ 20
- Open / Previous Close1.5300 / 1.4900
- Day Range
- 52 Week Range
- Volume34,606
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | MDNA |
|---|---|---|
| 09:32 ET | 1200 | 1.53 |
| 10:49 ET | 100 | 1.49 |
| 11:12 ET | 800 | 1.49 |
| 11:50 ET | 600 | 1.51 |
| 12:01 ET | 900 | 1.5 |
| 12:24 ET | 500 | 1.51 |
| 12:28 ET | 200 | 1.53 |
| 12:33 ET | 1500 | 1.53 |
| 01:08 ET | 200 | 1.54 |
| 01:56 ET | 100 | 1.53 |
| 01:58 ET | 100 | 1.53 |
| 02:32 ET | 16600 | 1.54 |
| 02:36 ET | 500 | 1.54 |
| 02:45 ET | 400 | 1.57 |
| 03:26 ET | 500 | 1.57 |
| 03:39 ET | 800 | 1.57 |
| 03:50 ET | 6500 | 1.56 |
| 04:00 ET | 2800 | 1.57 |
Nov 15, 2024
Medicenna Reports Second Quarter Fiscal 2025 Financial Results and Corporate Update, from 7:30AM ET on Friday Nov 15, 2024 by Dow Jones
7:30AM ET on Friday Nov 15, 2024 by Dow Jones
Nov 13, 2024
Nov 11, 2024
Nov 8, 2024
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Medicenna Therapeutics Corp | 120.0M | -4.2x | --- |
Oncolytics Biotech Inc | 102.5M | -3.6x | --- |
ME Therapeutics Holdings Inc | 88.2M | -21.1x | --- |
Satellos Bioscience Inc | 85.0M | -3.0x | --- |
Nurexone Biologic Inc | 53.1M | -6.7x | --- |
MustGrow Biologics Corp | 89.9M | -231.8x | --- |
Company Information
Medicenna Therapeutics Corp. is a Canada-based clinical-stage immunotherapy company. The Company's principal business activity is the development and commercialization of interleukin-2 (IL-2), interleukin-4 (IL-4) and interleukin-13 (IL-13) Superkines and Empowered Superkines for the treatment of cancer, inflammation and immune-mediated diseases. Its long-acting IL-2 Superkine, MDNA11, is an IL-2 with superior CD122 (IL-2 receptor beta) binding without CD25 (IL-2 receptor alpha) affinity, thereby preferentially stimulating cancer-killing effector T cells and NK cells. The Company’s IL-4 Empowered Superkine, bizaxofusp, has been studied in five clinical trials including a Phase IIb trial for recurrent glioblastoma (GBM). The Company’s early-stage Bifunctional SuperKine ImmunoTherapies (BiSKITs) program Targeted Metalloprotease Activated SuperKine (T-MASK) programs are designed to enhance the ability of Superkines to treat immunologically cold tumors.
Contact Information
- Headquarters
- 2 Bloor St W., 7Th FloorTORONTO, ON, Canada M4W 3E2
- Phone
- 416-648-5555
- Fax
- 416-648-5555
Executives
- Chairman of the Board, President, Chief Executive Officer
- Fahar Merchant
- Chief Financial Officer, Corporate Secretary
- David Hyman
- Chief Development Officer
- Rosemina Merchant
- Lead Independent Director
- Albert Beraldo
- Independent Director
- Karen Dawes
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $120.0M |
|---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 76.4M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.04 |
EPS | $-0.37 |
Book Value | $0.07 |
P/E Ratio | -4.2x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
